Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...

SpringWorks Therapeutics Inc. shares SWTX were on track for a record percentage gain on Tuesday after the company got the first U.S. regulatory approval for a drug targeting a rare type of ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stands against other best ...

In a continuation of its awareness and education efforts around desmoid tumors, SpringWorks Therapeutics has partnered with celebrity jewelry designer and patient advocate Jennifer Fisher. Just over ...

Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type ...

SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...